The global Myasthenia Gravis Treatment market growth is projected to reach US$ 1971 million in 2025 to US$ 2915 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.

Global Myasthenia Gravis Treatment Market Trends And Outlook 2025-31

The global Myasthenia Gravis Treatment market size is predicted to grow from US$ 1971 million in 2025 to US$ 2915 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031. Drug therapy for MG includes: (1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc. The major factors driving the market growth are increasing prevalence of myasthenia gravis, awareness for early diagnosis of myasthenia gravis, and adoption of new treatment options for myasthenia gravis. Rising prevalence of myasthenia gravis globally is one of the major drivers for the growth of the myasthenia gravis treatment market. For example, according to the Myasthenia Gravis Foundation of America, about 20 out of every 100,000 people in the United States have myasthenia gravis, and the disease is more common in women than men. Furthermore, the incidence of myasthenia gravis is increasing worldwide. Infinity Market Research newest research report, the ?Myasthenia Gravis Treatment Industry Forecast? looks at past sales and reviews total world Myasthenia Gravis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Myasthenia Gravis Treatment sales for 2025 through 2031. With Myasthenia Gravis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Myasthenia Gravis Treatment industry. This Insight Report provides a comprehensive analysis of the global Myasthenia Gravis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Myasthenia Gravis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Myasthenia Gravis Treatment market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Myasthenia Gravis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Myasthenia Gravis Treatment. This report presents a comprehensive overview, market shares, and growth opportunities of Myasthenia Gravis Treatment market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Monoclonal Antibodies &nbsp;&nbsp;&nbsp; Intravenous Immunoglobulin &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Specialist Clinic &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Amneal Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Astellas Pharma, Inc. &nbsp;&nbsp;&nbsp; Avadel Pharmaceuticals PLC &nbsp;&nbsp;&nbsp; Bausch Health Companies Inc. &nbsp;&nbsp;&nbsp; CSL Behring &nbsp;&nbsp;&nbsp; CuraVac, Inc. &nbsp;&nbsp;&nbsp; Argenx SE &nbsp;&nbsp;&nbsp; GlaxoSmithKline plc &nbsp;&nbsp;&nbsp; Immunovant, Inc. &nbsp;&nbsp;&nbsp; Mitsubishi Tanabe Pharma Corp. &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Co., Ltd. &nbsp;&nbsp;&nbsp; UCB Pharma &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd Key Questions Addressed in this Report What is the 10-year outlook for the global Myasthenia Gravis Treatment market? What factors are driving Myasthenia Gravis Treatment market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Myasthenia Gravis Treatment market opportunities vary by end market size? How does Myasthenia Gravis Treatment break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Myasthenia Gravis Treatment Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Myasthenia Gravis Treatment by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Myasthenia Gravis Treatment Segment by Type &nbsp;2.2.1 Monoclonal Antibodies &nbsp;2.2.2 Intravenous Immunoglobulin &nbsp;2.2.3 Other &nbsp;2.3 Myasthenia Gravis Treatment Sales by Type &nbsp;2.3.1 Global Myasthenia Gravis Treatment Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Myasthenia Gravis Treatment Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Myasthenia Gravis Treatment Sale Price by Type (2020-2025) &nbsp;2.4 Myasthenia Gravis Treatment Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Specialist Clinic &nbsp;2.4.3 Other &nbsp;2.5 Myasthenia Gravis Treatment Sales by Application &nbsp;2.5.1 Global Myasthenia Gravis Treatment Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Myasthenia Gravis Treatment Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Myasthenia Gravis Treatment Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Myasthenia Gravis Treatment Breakdown Data by Company &nbsp;3.1.1 Global Myasthenia Gravis Treatment Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Myasthenia Gravis Treatment Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Myasthenia Gravis Treatment Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Myasthenia Gravis Treatment Revenue by Company (2020-2025) &nbsp;3.2.2 Global Myasthenia Gravis Treatment Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Myasthenia Gravis Treatment Sale Price by Company &nbsp;3.4 Key Manufacturers Myasthenia Gravis Treatment Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Myasthenia Gravis Treatment Product Location Distribution &nbsp;3.4.2 Players Myasthenia Gravis Treatment Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Myasthenia Gravis Treatment by Geographic Region &nbsp;4.1 World Historic Myasthenia Gravis Treatment Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Myasthenia Gravis Treatment Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Myasthenia Gravis Treatment Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Myasthenia Gravis Treatment Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Myasthenia Gravis Treatment Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Myasthenia Gravis Treatment Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Myasthenia Gravis Treatment Sales Growth &nbsp;4.4 APAC Myasthenia Gravis Treatment Sales Growth &nbsp;4.5 Europe Myasthenia Gravis Treatment Sales Growth &nbsp;4.6 Middle East & Africa Myasthenia Gravis Treatment Sales Growth 5 Americas &nbsp;5.1 Americas Myasthenia Gravis Treatment Sales by Country &nbsp;5.1.1 Americas Myasthenia Gravis Treatment Sales by Country (2020-2025) &nbsp;5.1.2 Americas Myasthenia Gravis Treatment Revenue by Country (2020-2025) &nbsp;5.2 Americas Myasthenia Gravis Treatment Sales by Type (2020-2025) &nbsp;5.3 Americas Myasthenia Gravis Treatment Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Myasthenia Gravis Treatment Sales by Region &nbsp;6.1.1 APAC Myasthenia Gravis Treatment Sales by Region (2020-2025) &nbsp;6.1.2 APAC Myasthenia Gravis Treatment Revenue by Region (2020-2025) &nbsp;6.2 APAC Myasthenia Gravis Treatment Sales by Type (2020-2025) &nbsp;6.3 APAC Myasthenia Gravis Treatment Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Myasthenia Gravis Treatment by Country &nbsp;7.1.1 Europe Myasthenia Gravis Treatment Sales by Country (2020-2025) &nbsp;7.1.2 Europe Myasthenia Gravis Treatment Revenue by Country (2020-2025) &nbsp;7.2 Europe Myasthenia Gravis Treatment Sales by Type (2020-2025) &nbsp;7.3 Europe Myasthenia Gravis Treatment Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Myasthenia Gravis Treatment by Country &nbsp;8.1.1 Middle East & Africa Myasthenia Gravis Treatment Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Myasthenia Gravis Treatment Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Myasthenia Gravis Treatment Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Myasthenia Gravis Treatment Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Myasthenia Gravis Treatment &nbsp;10.3 Manufacturing Process Analysis of Myasthenia Gravis Treatment &nbsp;10.4 Industry Chain Structure of Myasthenia Gravis Treatment 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Myasthenia Gravis Treatment Distributors &nbsp;11.3 Myasthenia Gravis Treatment Customer 12 World Forecast Review for Myasthenia Gravis Treatment by Geographic Region &nbsp;12.1 Global Myasthenia Gravis Treatment Market Size Forecast by Region &nbsp;12.1.1 Global Myasthenia Gravis Treatment Forecast by Region (2026-2031) &nbsp;12.1.2 Global Myasthenia Gravis Treatment Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Myasthenia Gravis Treatment Forecast by Type (2026-2031) &nbsp;12.7 Global Myasthenia Gravis Treatment Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Amneal Pharmaceuticals, Inc. &nbsp;13.1.1 Amneal Pharmaceuticals, Inc. Company Information &nbsp;13.1.2 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Amneal Pharmaceuticals, Inc. Main Business Overview &nbsp;13.1.5 Amneal Pharmaceuticals, Inc. Latest Developments &nbsp;13.2 Astellas Pharma, Inc. &nbsp;13.2.1 Astellas Pharma, Inc. Company Information &nbsp;13.2.2 Astellas Pharma, Inc. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Astellas Pharma, Inc. Main Business Overview &nbsp;13.2.5 Astellas Pharma, Inc. Latest Developments &nbsp;13.3 Avadel Pharmaceuticals PLC &nbsp;13.3.1 Avadel Pharmaceuticals PLC Company Information &nbsp;13.3.2 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Avadel Pharmaceuticals PLC Main Business Overview &nbsp;13.3.5 Avadel Pharmaceuticals PLC Latest Developments &nbsp;13.4 Bausch Health Companies Inc. &nbsp;13.4.1 Bausch Health Companies Inc. Company Information &nbsp;13.4.2 Bausch Health Companies Inc. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Bausch Health Companies Inc. Main Business Overview &nbsp;13.4.5 Bausch Health Companies Inc. Latest Developments &nbsp;13.5 CSL Behring &nbsp;13.5.1 CSL Behring Company Information &nbsp;13.5.2 CSL Behring Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.5.3 CSL Behring Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 CSL Behring Main Business Overview &nbsp;13.5.5 CSL Behring Latest Developments &nbsp;13.6 CuraVac, Inc. &nbsp;13.6.1 CuraVac, Inc. Company Information &nbsp;13.6.2 CuraVac, Inc. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 CuraVac, Inc. Main Business Overview &nbsp;13.6.5 CuraVac, Inc. Latest Developments &nbsp;13.7 Argenx SE &nbsp;13.7.1 Argenx SE Company Information &nbsp;13.7.2 Argenx SE Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.7.3 Argenx SE Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Argenx SE Main Business Overview &nbsp;13.7.5 Argenx SE Latest Developments &nbsp;13.8 GlaxoSmithKline plc &nbsp;13.8.1 GlaxoSmithKline plc Company Information &nbsp;13.8.2 GlaxoSmithKline plc Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 GlaxoSmithKline plc Main Business Overview &nbsp;13.8.5 GlaxoSmithKline plc Latest Developments &nbsp;13.9 Immunovant, Inc. &nbsp;13.9.1 Immunovant, Inc. Company Information &nbsp;13.9.2 Immunovant, Inc. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Immunovant, Inc. Main Business Overview &nbsp;13.9.5 Immunovant, Inc. Latest Developments &nbsp;13.10 Mitsubishi Tanabe Pharma Corp. &nbsp;13.10.1 Mitsubishi Tanabe Pharma Corp. Company Information &nbsp;13.10.2 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Mitsubishi Tanabe Pharma Corp. Main Business Overview &nbsp;13.10.5 Mitsubishi Tanabe Pharma Corp. Latest Developments &nbsp;13.11 Novartis AG &nbsp;13.11.1 Novartis AG Company Information &nbsp;13.11.2 Novartis AG Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.11.3 Novartis AG Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Novartis AG Main Business Overview &nbsp;13.11.5 Novartis AG Latest Developments &nbsp;13.12 Takeda Pharmaceutical Co., Ltd. &nbsp;13.12.1 Takeda Pharmaceutical Co., Ltd. Company Information &nbsp;13.12.2 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Takeda Pharmaceutical Co., Ltd. Main Business Overview &nbsp;13.12.5 Takeda Pharmaceutical Co., Ltd. Latest Developments &nbsp;13.13 UCB Pharma &nbsp;13.13.1 UCB Pharma Company Information &nbsp;13.13.2 UCB Pharma Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.13.3 UCB Pharma Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 UCB Pharma Main Business Overview &nbsp;13.13.5 UCB Pharma Latest Developments &nbsp;13.14 AstraZeneca &nbsp;13.14.1 AstraZeneca Company Information &nbsp;13.14.2 AstraZeneca Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.14.3 AstraZeneca Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 AstraZeneca Main Business Overview &nbsp;13.14.5 AstraZeneca Latest Developments &nbsp;13.15 F. Hoffmann-La Roche Ltd &nbsp;13.15.1 F. Hoffmann-La Roche Ltd Company Information &nbsp;13.15.2 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product Portfolios and Specifications &nbsp;13.15.3 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 F. Hoffmann-La Roche Ltd Main Business Overview &nbsp;13.15.5 F. Hoffmann-La Roche Ltd Latest Developments 14 Research Findings and Conclusion

Report	Global Myasthenia Gravis Treatment Market Growth 2025-2031
Selected License	Multi ID: LPI10590

Buyer Information

Order Summary